A Phase 3 interventional study of Placebo and BRV 2.5 mg in Unverricht-Lundborg Disease, sponsored by UCB Pharma. Completed at 18 sites in 8 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-05-31.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Myoclonus with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Myoclonus · United States.
Among the 13 studies in Myoclonus with a site in United States, this one is the only one that started in 2006, is the only one in phase 3, and was the 8th registered.
20 studies on the registry are indexed under Myoclonus; 6 are open to participants now.
Browse Myoclonus studies →6 of the 13 studies in Myoclonus with a site in United States are open now. Recruiting first, the newest first:
Boston Children's Hospital · Sites in United States
Ages 0–30
Boston Children's Hospital · Sites in United States
Boston Children's Hospital · Sites in United States
Ages 0–18
Massachusetts Eye and Ear Infirmary · Sites in United States
Healthy volunteers
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Myoclonus studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 1
First in 1997; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 50 across 11 interventional studies indexed under Myoclonus.
Median enrollment 30 across the 5 interventional studies, 250 across the 8 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 7 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
UCB S.A. has 2 studies filed under Myoclonus — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Myoclonus with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Placebo twice a day (bid), 14 weeks (2 week Up-Titration Period + 12 week Maintenance Period)
Other: Placebo
Brivaracetam (BRV) 5 mg/day 5 mg twice a day (bid) using 2.5 mg tablets for 12 weeks (after 2 week Up- Titration Period)
Drug: BRV 2.5 mg
Brivaracetam (BRV) 150 mg/day 150 mg twice a day (bid) using 25 mg and 50 mg tablets for 12 weeks (after 2 week Up-Titration Period)
Drug: BRV 25 mg · Drug: BRV 50 mg
* Pharmaceutical Form: Tablet * Concentration: 2.5 mg, 25 mg and 50 mg * Route of Administration: Oral use
* Pharmaceutical Form: Tablet * Concentration: 2.5 mg * Route of Administration: Oral use
Also known as: ucb34714
* Pharmaceutical Form: Tablet * Concentration: 25 mg * Route of Administration: Oral use
* Pharmaceutical Form: Tablet * Concentration: 50 mg * Route of Administration: Oral use
Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4)
The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit.
Time frame: From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Percent Change From Baseline to the End of Treatment Period on the Functional Disability Score (Unified Myoclonus Rating Scale (UMRS) Section 5)
The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit.
Time frame: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Percent Change From Baseline to the End of Treatment Period on the Stimulus Sensitivity Score (Unified Myoclonus Rating Scale (UMRS) Section 3)
The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit.
Time frame: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Percent Change From Baseline to the End of Treatment Period on the Myoclonus Patient Questionnaire (Unified Myoclonus Rating Scale (UMRS) Section 1)
The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit.
Time frame: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Global Evaluation Score (Investigator) at the End of Treatment Period
The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement).
Time frame: End of Treatment Period (Week 14 or Early Discontinuation Visit)
72 subjects were screened, 56 subjects were randomized. Participant Flow refers to all subjects randomized who are identical with the Intent-To-Treat (ITT) Population, which consists of all randomized subjects who took at least one dose of study medication.
| Milestone | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day |
|---|---|---|---|
| Started | 18 | 20 | 18 |
| Completed | 17 | 20 | 17 |
| Not completed | 1 | 0 | 1 |
| Withdrew: Sae, non-fatal | 1 | 0 | 0 |
| Withdrew: Ae, non-serious non-fatal | 0 | 0 | 1 |
The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit.
| Percent change | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day |
|---|---|---|---|
| Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4) | 17.45 (-170.0 to 61.5) | -4.60 (-430.0 to 81.8) | 12.34 (-58.3 to 96.9) |
The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit.
| Percent change | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day |
|---|---|---|---|
| Percent Change From Baseline to the End of Treatment Period on the Functional Disability Score (Unified Myoclonus Rating Scale (UMRS) Section 5) | 0.00 (-380.0 to 53.8) | 0.00 (-380.0 to 60.0) | 0.00 (-85.7 to 75.0) |
The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit.
| Percent change | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day |
|---|---|---|---|
| Percent Change From Baseline to the End of Treatment Period on the Stimulus Sensitivity Score (Unified Myoclonus Rating Scale (UMRS) Section 3) | 0.00 (-300.0 to 100.0) | 43.44 (-300.0 to 100.0) | 0.00 (-300.0 to 100.0) |
The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit.
| Percent change | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day |
|---|---|---|---|
| Percent Change From Baseline to the End of Treatment Period on the Myoclonus Patient Questionnaire (Unified Myoclonus Rating Scale (UMRS) Section 1) | -9.68 (-125.0 to 63.0) | 0.00 (-95.0 to 55.6) | 5.41 (-24.0 to 100.0) |
The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement).
| percentage of participants | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day |
|---|---|---|---|
| Marked improvement | 0 | 10.0 | 11.1 |
| Moderate improvement | 11.1 | 0 | 11.1 |
| Slight improvement | 33.3 | 30.0 | 33.3 |
| No change | 50.0 | 50.0 | 33.3 |
| Slight worsening | 0 | 10.0 | 5.6 |
| Moderate worsening | 0 | 0 | 5.6 |
| Marked worsening | 5.6 | 0 | 0 |
Collected over Adverse Events (AEs) were collected from Visit 1 (Week -2) until final Visit 10 (Week 18).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/18 (11.1%) | 13/18 (72.2%) |
| Brivaracetam 5 mg/Day | — | 3/20 (15%) | 13/20 (65%) |
| Brivaracetam 150 mg/Day | — | 2/18 (11.1%) | 15/18 (83.3%) |
| Event | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day |
|---|---|---|---|
| AppendicitisInfections and infestations | 0/18 | 2/20 | 0/18 |
| PyrexiaGeneral disorders | 1/18 | 0/20 | 0/18 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/18 | 0/20 | 1/18 |
| ConvulsionNervous system disorders | 1/18 | 1/20 | 0/18 |
| Grand mal convulsionNervous system disorders | 0/18 | 0/20 | 1/18 |
| Status epilepticusNervous system disorders | 0/18 | 0/20 | 1/18 |
| Myoclonic epilepsyNervous system disorders | 1/18 | 0/20 | 0/18 |
| Attention-seeking behaviorPsychiatric disorders | 1/18 | 0/20 | 0/18 |
| Event | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day |
|---|---|---|---|
| HeadacheNervous system disorders | 7/18 | 3/20 | 2/18 |
| SomnolenceNervous system disorders | 2/18 | 3/20 | 4/18 |
| MyoclonusNervous system disorders | 1/18 | 4/20 | 3/18 |
| FatigueGeneral disorders | 2/18 | 1/20 | 3/18 |
| NasopharyngitisInfections and infestations | 3/18 | 1/20 | 1/18 |
| TremorNervous system disorders | 3/18 | 0/20 | 1/18 |
| Abdominal pain upperGastrointestinal disorders | 2/18 | 2/20 | 0/18 |
| DiarrhoeaGastrointestinal disorders | 2/18 | 1/20 | 1/18 |
| ConstipationGastrointestinal disorders | 2/18 | 0/20 | 1/18 |
| Otitis externaInfections and infestations | 2/18 | 0/20 | 0/18 |
The Baseline Analysis Population contains all randomized subjects who are identical with the Intent-To-Treat (ITT) population.
| Age, Categorical(Participants) | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day | Total Title |
|---|---|---|---|---|
| <=18 years | 0 | 1 | 1 | 2 |
| Between 18 and 65 years | 18 | 19 | 17 | 54 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day | Total Title |
|---|---|---|---|---|
| Mean | 34.3 ± 9.2 | 35.8 ± 10.9 | 33.7 ± 11.4 | 34.65 ± 10.38 |
| Sex: Female, Male(Participants) | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day | Total Title |
|---|---|---|---|---|
| Female | 12 | 11 | 9 | 32 |
| Male | 6 | 9 | 9 | 24 |
| Region of Enrollment(participants) | Placebo | Brivaracetam 5 mg/Day | Brivaracetam 150 mg/Day | Total Title |
|---|---|---|---|---|
| Serbia | 2 | 2 | 2 | 6 |
| France | 3 | 2 | 3 | 8 |
| United States | 2 | 3 | 4 | 9 |
| Canada | 4 | 3 | 2 | 9 |
| Finland | 3 | 4 | 2 | 9 |
| Russian Federation | 2 | 3 | 3 | 8 |
| Israel | 0 | 0 | 2 | 2 |
| Tunisia | 2 | 3 | 0 | 5 |
The record gives a start of Nov 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 8 years 3 months after primary completion. A results delay was requested in Sep 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam